摘要
目的探讨偶联血管内皮生长因子受体（VEGFR）2单克隆抗体的尿素免疫脂质体对血管瘤血管内皮细胞（HVEC）的增殖影响，对血管瘤是否有更好的靶向治疗作用。方法通过细胞毒性实验的多种方法，观察尿素免疫脂质体作用后HVEC的形态和生长曲线变化，检测HVEC细胞存活率、细胞杀伤率及细胞群体倍增时间。结果HVEC细胞存活率与尿素免疫脂质体终质量浓度呈显著负相关。尿素免疫脂质体对HVEC的半效应量（ID50）约26mg。2．6％尿素免疫脂质体的细胞杀伤率为99．91％。2．6％尿素免疫脂质体作用HVEC后，HVEC的细胞增殖一直处于抑制状态，细胞群体倍增时间无法算出，生长曲线一直呈下降趋势，尿素免疫脂质体对HVEC的增殖抑制作用具有明显的持续效应，尿素免疫脂质体从接种药物开始就对HVEC的增值进行了抑制。结论尿素免疫脂质体对HVEC呈时间依赖性和剂量依赖性生长抑制作用，尿素免疫脂质体具有靶向治疗血管瘤的作用。
Objective To evaluate the effect and targeting ability of medical urea immunoliposomes conjugated with monoclonal antibody of vascular endothelial growth factor receptor2 （VEGFR2） on proliferation of hemangioma vascular endothelial cells （HVEC） in vitro. Methods Many kinds of eytotoxicity experiment methods were used to observe the changes in morphology and growth curve of HVEC, and detect survival rate, killing ratio and doubling time of HVEC in vitro after HVEC were exposed to medical urea immunoliposomes. Results The survival rate of HVEC showed a negative correlation with medical urea immunoliposomes final concentration. The median infective dose of medical urea irnmunoliposomes for HVEC was about 26 mg. The killing ratio of 2.6% medical urea immunoliposomes for HVEC was about 99.91%. After HVEC were exposed to 2.6% medical urea immunoliposomes, the proliferation of HVEC was inhibited all the time and the growth curve exhibited obviously downward tendency all the time; The doubling time of HVEC was impossibly calculated according to formula. The medical urea immunoliposomes possessed persistently inhibitory action on proliferation of HVEC, and scarcely had the medical urea immunoliposomes acted upon HVEC when the medical urea immunoliposomes inhibited proliferation of HVEC. Conclusion The medical urea immunoliposomes inhibited the growth of HVEC in a dose-and time-dependent manner and had better action of targeting therapy for hemangioma.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2007年第2期153-155,F0003,共4页
Chinese Journal of Experimental Surgery
